Artikler med krav om offentlig adgang - Richard P. Baum, MD PhDFå flere oplysninger
Ikke tilgængelige nogen steder: 2
Highly improved metabolic stability and pharmacokinetics of indium-111-DOTA-gastrin conjugates for targeting of the gastrin receptor
P Kolenc-Peitl, R Mansi, ML Tamma, T Gmeiner-Stopar, M Sollner-Dolenc, ...
Journal of medicinal chemistry 54 (8), 2602-2609, 2011
Krav: Swiss National Science Foundation
Generator-Based Radiopharmaceuticals for PET Dosimetry Before, During, and After Endoradiotherapy
F Rösch, RP Baum
Therapeutic Nuclear Medicine, 83-94, 2014
Krav: European Commission
Tilgængelige et sted: 44
Everolimus for advanced pancreatic neuroendocrine tumors
JC Yao, MH Shah, T Ito, CL Bohas, EM Wolin, E Van Cutsem, TJ Hobday, ...
New England Journal of Medicine 364 (6), 514-523, 2011
Krav: US National Institutes of Health
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J Strosberg, G El-Haddad, E Wolin, A Hendifar, J Yao, B Chasen, E Mittra, ...
New England Journal of Medicine 376 (2), 125-135, 2017
Krav: US National Institutes of Health
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
JC Yao, N Fazio, S Singh, R Buzzoni, C Carnaghi, E Wolin, J Tomasek, ...
The Lancet 387 (10022), 968-977, 2016
Krav: US National Institutes of Health
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
JJ Zaknun, L Bodei, J Mueller-Brand, ME Pavel, RP Baum, D Hörsch, ...
European journal of nuclear medicine and molecular imaging 40, 800-816, 2013
Krav: US National Institutes of Health
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas
MH Kulke, LB Anthony, DL Bushnell, WW De Herder, SJ Goldsmith, ...
Pancreas 39 (6), 735-752, 2010
Krav: US National Institutes of Health
Consensus guidelines for the management and treatment of neuroendocrine tumors
PL Kunz, D Reidy-Lagunes, LB Anthony, EM Bertino, K Brendtro, JA Chan, ...
Pancreas 42 (4), 557-577, 2013
Krav: US National Institutes of Health
Processing of generator-produced 68Ga for medical application
KP Zhernosekov, DV Filosofov, RP Baum, P Aschoff, H Bihl, AA Razbash, ...
Journal of Nuclear Medicine 48 (10), 1741-1748, 2007
Krav: German Research Foundation
68Ga-and 177Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies
M Weineisen, M Schottelius, J Simecek, RP Baum, A Yildiz, S Beykan, ...
Journal of Nuclear Medicine 56 (8), 1169-1176, 2015
Krav: German Research Foundation
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial
J Strosberg, E Wolin, B Chasen, M Kulke, D Bushnell, M Caplin, RP Baum, ...
Journal of Clinical Oncology 36 (25), 2578-2584, 2018
Krav: US National Institutes of Health
The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas
JR Strosberg, D Coppola, DS Klimstra, AT Phan, MH Kulke, GA Wiseman, ...
Pancreas 39 (6), 799-800, 2010
Krav: US National Institutes of Health
Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma
E Van Cutsem, MA Tempero, D Sigal, DY Oh, N Fazio, T Macarulla, ...
Journal of Clinical Oncology 38 (27), 3185-3194, 2020
Krav: US National Institutes of Health
Safety and efficacy of 68Ga-DOTATATE PET/CT for diagnosis, staging, and treatment management of neuroendocrine tumors
SA Deppen, E Liu, JD Blume, J Clanton, C Shi, LB Jones-Jackson, ...
Journal of Nuclear Medicine 57 (5), 708-714, 2016
Krav: US National Institutes of Health, US Department of Veterans Affairs
Pancreas cancer‐associated weight loss
AE Hendifar, MQB Petzel, TA Zimmers, CS Denlinger, LM Matrisian, ...
The oncologist 24 (5), 691-701, 2019
Krav: US National Institutes of Health, US Department of Veterans Affairs …
PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy
L Bodei, MS Kidd, A Singh, WA Van Der Zwan, S Severi, IA Drozdov, ...
European journal of nuclear medicine and molecular imaging 45, 1155-1169, 2018
Krav: US National Institutes of Health
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
C Kratochwil, WP Fendler, M Eiber, MS Hofman, L Emmett, J Calais, ...
European journal of nuclear medicine and molecular imaging 50 (9), 2830-2845, 2023
Krav: US Department of Defense, US National Institutes of Health, National Health …
PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest
L Bodei, MS Kidd, A Singh, WA van der Zwan, S Severi, IA Drozdov, ...
European journal of nuclear medicine and molecular imaging 47, 895-906, 2020
Krav: US National Institutes of Health
Neuroendocrine neoplasms of the small bowel and pancreas
AK Clift, M Kidd, L Bodei, C Toumpanakis, RP Baum, K Oberg, IM Modlin, ...
Neuroendocrinology 110 (6), 444-476, 2020
Krav: US National Institutes of Health
Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study
J Strosberg, PL Kunz, A Hendifar, J Yao, D Bushnell, MH Kulke, RP Baum, ...
European journal of nuclear medicine and molecular imaging 47, 2372-2382, 2020
Krav: US National Institutes of Health
Oplysninger om publikation og økonomisk støtte registreres automatisk af et computerprogram